Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Buy

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Incyte Genomics Inc (INCY)

Services-commercial Physical & Biological Research

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

1801 AUGUSTINE CUT-OFF
WILMINGTON, DE

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/03/1993

Market Cap

12,013,300,250

Shares Outstanding

224,110,000

Weighted SO

224,109,238

Total Employees

N/A

Upcoming Earnings

07/30/2024

Similar Tickers

ALNY --.--%

UTHR --.--%

RARE --.--%

APLS --.--%

BGNE --.--%

BMRN --.--%

IMGN --.--%

RXDX --.--%

ARWR --.--%

Beta

0.7340

Last Div

0.0000

Range

50.27-70.36

Chg

0.6950

Avg Vol

3486635

Mkt Cap

12013300250

Exch

NASDAQ

Country

US

Phone

302 498 6700

DCF Diff

-75.7765

DCF

138.1165

Div Yield

0.0000

P/S

3.1147

EV Multiple

46.4621

P/FV

4.5407

Div Yield %

0.0000

P/E

139.8701

PEG

9.6371

Payout

0.0000

Current Ratio

1.9200

Quick Ratio

1.8446

Cash Ratio

0.7384

DSO

69.9384

DIO

129.4838

Op Cycle

199.4222

DPO

190.5201

CCC

8.9021

Gross Margin

0.9264

Op Margin

0.0043

Pretax Margin

0.0910

Net Margin

0.0252

Eff Tax Rate

0.7229

ROA

0.0209

ROE

0.0210

ROCE

0.0050

NI/EBT

0.2771

EBT/EBIT

21.1071

EBIT/Rev

0.0043

Debt Ratio

0.0081

D/E

0.0125

LT Debt/Cap

0.0095

Total Debt/Cap

0.0124

Int Coverage

13.8633

CF/Debt

-1.6296

Equity Multi

1.5555

Rec Turnover

5.2189

Pay Turnover

1.9158

Inv Turnover

2.8189

FA Turnover

4.8975

Asset Turnover

0.8274

OCF/Share

-0.2805

FCF/Share

-0.6395

Cash/Share

6.9640

OCF/Sales

-0.0159

FCF/OCF

2.2802

CF Coverage

-1.6296

ST Coverage

-6.9508

CapEx Coverage

-0.7811

Div&CapEx Cov

-0.7811

P/BV

4.5407

P/B

4.5407

P/S

3.1147

P/E

139.8701

P/FCF

-86.1027

P/OCF

-222.4074

P/CF

-222.4074

PEG

9.6371

P/S

3.1147

EV Multiple

46.4621

P/FV

4.5407

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 22, 04:30 Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight Benzinga Jan 10, 15:12 Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations MarketWatch Jan 09, 09:13 Here are Wall Street’s favorite stocks in the sector expected to grow profits the most in 2024 Zacks Investment Research Nov 23, 09:27 Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug Benzinga Nov 21, 15:05 Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness

Revenue Product Segmentation